Skip to main content

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC
menu

Megan A. Baumgart, M.D.

Contact Information

Phone Numbers

Appointment: (585) 275-5823

Administrative: (585) 275-9319

Fax: (585) 273-1042

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

Patient Care Setting

Cancer

Biography

I chose the field of oncology because I want to help patients through one of the most difficult experiences a person can have.

Cancer treatment requires a team approach involving the patient, medical oncologist, nurses and support staff, as well as other medical teams such as radiation oncology and surgery who are often part of a patient's care. I work with patients to help them understand the overall treatment plan – especially the role of chemotherapy in the treatment of their disease – and support them throughout the course of treatment.

I am optimistic about the future of cancer treatment and want to work towards finding new and better treatment strategies for lung and head and neck cancers through the development of our clinical trials program. We currently have several clinical trials evaluating the role of immunotherapy for the treatment of metastatic head and neck cancers open for enrollment, as well as other clinical trials focused on answering important questions regarding the management of these diseases.

Conditions I Treat

- Small cell lung cancer
- Non-small cell lung cancer
- Head and neck cancers
- Thyroid cancer

Credentials

Specialties

  • Internal Medicine - American Board of Internal Medicine
  • Medical Oncology - American Board of Internal Medicine

Education

2007
MD | Albany Medical College of Union University

Post-doctoral Training & Residency

07/01/2011 - 06/30/2014
Fellowship in Medical Oncology at Yale New Haven Hospital

07/01/2008 - 06/30/2010
Residency in Internal Medicine at Rhode Island Hospital

06/20/2007 - 06/30/2008
Internship in Internal Medicine at Rhode Island Hospital

VIEW ALL expand_more

Awards

2019 - Present
Early Career Women Faculty Leadership Development Seminar
Sponsor: AAMC Application Selection Committee

2014
Annual Award for Outstanding Oncology Research
Sponsor: Yale University Medical Oncology and Hematology Fellowship
Location: New Haven, CT

2007
Albany Medical College- Distinction in Biomedical Ethics
Location: Albany, NY

VIEW ALL expand_more

Clinical Trials

A pilot study of pembrolizumab and single agent chemotherapy as first line treatment for patients with locally advanced or metastatic non-small cell lung cancer with Eastern Cooperative Oncology Group (ECOG) performance status of 2

Lead Researcher: Megan A Baumgart

The purpose of this study is to understand if treatment with one chemotherapy medication combined with immune therapy (pembrolizumab) is tolerable and effective for patients with lung cancer and performance status of 2 (PS2), which means you have limitations in carrying out certain activities or spend up to half of your day resting.

View Study Details

A Phase II Study of LOXO-292 in Patients With RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)

Lead Researcher: Megan A Baumgart

This phase II LUNG-MAP treatment trial studies how well selpercatinib works in treating patients with RET fusion-positive non-small cell lung cancer that is stage IV or has come back (recurrent). Selpercatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

View Study Details

A Phase II Study of Talazoparib Plus Avelumab in Patients with Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (LUNG-MAP Sub-Study) [S1900C]

Lead Researcher: Megan A Baumgart

This phase II LUNG-MAP treatment trial studies how well combination treatment (talazoparib plus avelumab) works in treating patients with non-squamous non-small cell lung cancer that has an STK11 gene mutation and has come back (recurrent) or is stage IV. Talazoparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Immunotherapy drugs given as single therapies or in combination with chemotherapy do not appear to work as well in lung cancer cells with mutations in the STK11 gene versus those that do not have the mutation. Adding the medicine talazoparib to the immunotherapy drug avelumab may work better in treating lung cancers that have an STK11 gene mutation.

View Study Details

(S1800A) A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)

Lead Researcher: Megan A Baumgart

This phase II Lung-MAP non-Match treatment trial studies how well ramucirumab and pembrolizumab work versus standard of care in treating patients with non-small cell lung cancer that is stage IV or has come back. Immunotherapy with monoclonal antibodies, such as ramucirumab and pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in standard of care chemotherapy for non-small cell lung cancer, such as docetaxel, gemcitabine hydrochloride, and pemetrexed, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ramucirumab and pembrolizumab together may work better in treating patients with non-small lung cancer compared to standard of care.

View Study Details

CLUN18052: EA5161: Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) alone or in Combination with Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (ED-SCLC)

Lead Researcher: Megan A Baumgart

If you decide to participate in this study you will be assigned to one of the two treatment groups by chance. This is done by chance because no one knows if one study group is better or worse than the other. Group 1 will receive the study drug nivolumab in combination with the usual chemotherapy regimen of platinum (cisplatin or carboplatin) and etoposide administered by an intravenous (IV) infusion. Group 2 will receive the usual chemotherapy alone administered by an intravenous (IV) infusion.

View Study Details

ILUN17100: Phase 1b/2 Study of VX15/2503 in combination with avelumab in advanced non-small cell lung cancer,ILUN17100: Phase 1b/2 Study of VX15/2503 in combination with avelumab in advanced non-small cell lung cancer,ILUN17100: Phase 1b/2 Study of VX15/2503 in combination with avelumab in advanced non-small cell lung cancer

Lead Researcher: Megan A Baumgart

There are 2 phases in this study. If you are in the dose finding phase of the study, the dose level of VX15/2503 that you receive is depends on when you enter the study. The first group of subjects in this study will get a low dose of VX15/2503. If that dose is well tolerated by those subjects, then the next group of subjects will get a higher dose of VX15/2503. This will continue until the highest tolerable, safe dose of VX15/2503 is reached. The dose expansion phase will begin begin after the highest tolerable dose, or recommended phase 2 dosage (dose to be tested in expansion), has been identified in the dose finding phase of the trial.

View Study Details

Publications

Journal Articles

2017
Baumgart, M.; Bazhenova, L.; Haggstrom, D.; Baranda, J.; Belani, C. "PUB031 PRIMAL: A Phase 1b Study of PEGPH20 plus Docetaxel in Patients with Previously Treated Hyaluronan (HA)-High Advanced NSCLC" . Journal of Thoracic Oncology. 2017; 12(1): S1465.

6/1/2015
Abu-Khalaf MM, Baumgart MA, Gettinger SN, Doddamane I, Tuck DP, Hou S, Chen N, Sullivan C, Lezon-Geyda K, Zelterman D, Hatzis C, Deshpande H, Digiovanna MP, Azodi M, Schwartz PE, Harris LN. "Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel in patients with advanced solid tumors." Cancer.. 2015 Jun 1; 121(11):1817-26. Epub 2015 Feb 03.

2015
Baumgart, M. "New molecular targets on the horizon in non-small cell lung cancer" . American Journal of Hematology and Oncology. 2015; 11(6): 10-13.

VIEW ALL PUBLICATIONS